Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (331-340 of 516) with videos related to

Pageof 52
Sort By:
Blood Cancer Journal|October 12, 2018
Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestryLinda B Baughn, Kathryn Pearce, Dirk Larson, et al.
Leukemia|June 17, 2024
Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumabNadine Abdallah, David Murray, Angela Dispenzieri, et al.
Cancer Research|April 6, 2007
Molecular dissection of hyperdiploid multiple myeloma by gene expression profilingWee J Chng, Shaji Kumar, Scott Vanwier, et al.
Cancers|November 27, 2025
Whole-Exome Sequencing-Based Linkage Analysis of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS) PedigreesAlyssa I Clay-Gilmour, Nicola J Camp, Xiaomu Wei, et al.
Hemasphere|December 31, 2025
Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab eraAbdul-Hamid Bazarbachi, Saurabh Zanwar, Ute Hegenbart, et al.
Blood Cancer Journal|February 21, 2019
Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutationsJess F Peterson, Ross A Rowsey, Cherisse A Marcou, et al.
Blood Cancer Journal|January 25, 2022
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trialMeletios A Dimopoulos, Fredrik Schjesvold, Vadim Doronin, et al.
British Journal of Haematology|May 10, 2026
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotypeMatthew J Rees, Binoy Yohannan, Susan Geyer, et al.
Mayo Clinic Proceedings|May 6, 2015
Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin depositsGauri Bhutani, Samih H Nasr, Samar M Said, et al.
Blood|April 14, 2012
Clonal competition with alternating dominance in multiple myelomaJonathan J Keats, Marta Chesi, Jan B Egan, et al.
Pageof 52

Showing results (331-340 of 516) with videos related to

Sort By:
Pageof 52
Blood Cancer Journal|October 12, 2018
Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestryLinda B Baughn, Kathryn Pearce, Dirk Larson, et al.
Leukemia|June 17, 2024
Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumabNadine Abdallah, David Murray, Angela Dispenzieri, et al.
Cancer Research|April 6, 2007
Molecular dissection of hyperdiploid multiple myeloma by gene expression profilingWee J Chng, Shaji Kumar, Scott Vanwier, et al.
Cancers|November 27, 2025
Whole-Exome Sequencing-Based Linkage Analysis of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS) PedigreesAlyssa I Clay-Gilmour, Nicola J Camp, Xiaomu Wei, et al.
Hemasphere|December 31, 2025
Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab eraAbdul-Hamid Bazarbachi, Saurabh Zanwar, Ute Hegenbart, et al.
Blood Cancer Journal|February 21, 2019
Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutationsJess F Peterson, Ross A Rowsey, Cherisse A Marcou, et al.
Blood Cancer Journal|January 25, 2022
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trialMeletios A Dimopoulos, Fredrik Schjesvold, Vadim Doronin, et al.
British Journal of Haematology|May 10, 2026
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotypeMatthew J Rees, Binoy Yohannan, Susan Geyer, et al.
Mayo Clinic Proceedings|May 6, 2015
Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin depositsGauri Bhutani, Samih H Nasr, Samar M Said, et al.
Blood|April 14, 2012
Clonal competition with alternating dominance in multiple myelomaJonathan J Keats, Marta Chesi, Jan B Egan, et al.
Pageof 52